FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306661090> ?p ?o ?g. }

• W4306661090 abstract "Abstract Background Uveal melanoma is the most common primary intraocular tumor in adults. In Sweden, 60 to 100 patients are diagnosed with the disease each year. Almost half of the patients develop metastases, with a median survival time of 1 year once metastases are detected. The primary ocular tumor is typically treated with either enucleation or brachytherapy, and no adjuvant treatment is added. Melatonin is an indolamine hormone that has improved survival in previous trials with patients diagnosed with various cancers, including advanced cutaneous melanoma. Side effects have been mild. We aim to investigate if adjuvant treatment with melatonin for 5 years following diagnosis of non-metastasized uveal melanoma can decrease the occurrence of metastases. Methods An open-label, prospective, 5-year randomized clinical trial (RCT) will be conducted at St. Erik Eye Hospital. Patients (n = 100) diagnosed with non-metastatic uveal melanoma will be included in this trial and randomized to either treatment with adjuvant melatonin 20 mg (4 tablets of 5 mg) at 10 pm for five years, or to standard follow-up (control group). The primary outcome measurement is the number of patients that have developed metastases 5 years after randomization. The secondary outcomes are overall survival, risk of developing other cancers, overall survival after detection of metastases, and differences in the occurrence of adverse events (AE) and serious adverse events (SAE) between the groups. Discussion Melatonin has been found to positively impact our immune system, inhibit angiogenesis, stimulate apoptosis in malignant cells, and act as a potent antioxidant. Previous clinical trials have used similar doses of melatonin with positive results, particularly in advanced stages of cancer. Previous animal and human studies have found the toxicity of the hormone to be low. Considering the potential benefits and limited risks of melatonin, as well as its global availability, it may be a suitable candidate for an adjuvant treatment in patients with uveal melanoma. Trial registration Our trial protocol has been approved and registered by the Swedish Medical Products Agency on June 22, 2022 (EudraCT 2022-500307-49-00). Our trial registration number is NCT05502900 and the date of registration is August 16, 2022." @default.
• W4306661090 created "2022-10-18" @default.
• W4306661090 creator A5030291200 @default.
• W4306661090 creator A5056026487 @default.
• W4306661090 creator A5067372873 @default.
• W4306661090 date "2022-10-17" @default.
• W4306661090 modified "2023-10-18" @default.
• W4306661090 title "Adjuvant Melatonin for Uveal Melanoma (AMUM): Protocol for a Randomized Open-label Phase III Study" @default.
• W4306661090 cites W1881548596 @default.
• W4306661090 cites W1892087797 @default.
• W4306661090 cites W1959621890 @default.
• W4306661090 cites W1964369071 @default.
• W4306661090 cites W1969934516 @default.
• W4306661090 cites W1971445017 @default.
• W4306661090 cites W1982209205 @default.
• W4306661090 cites W1990403579 @default.
• W4306661090 cites W1991484632 @default.
• W4306661090 cites W2011485266 @default.
• W4306661090 cites W2012484330 @default.
• W4306661090 cites W2015846386 @default.
• W4306661090 cites W2018300894 @default.
• W4306661090 cites W2018629519 @default.
• W4306661090 cites W2023777719 @default.
• W4306661090 cites W2035624349 @default.
• W4306661090 cites W2036538458 @default.
• W4306661090 cites W2049866899 @default.
• W4306661090 cites W2053009135 @default.
• W4306661090 cites W2055835855 @default.
• W4306661090 cites W2066233701 @default.
• W4306661090 cites W2077129521 @default.
• W4306661090 cites W2077304413 @default.
• W4306661090 cites W2085104178 @default.
• W4306661090 cites W2089223199 @default.
• W4306661090 cites W2091174084 @default.
• W4306661090 cites W2091872457 @default.
• W4306661090 cites W2094785671 @default.
• W4306661090 cites W2099986080 @default.
• W4306661090 cites W2147850345 @default.
• W4306661090 cites W2171811563 @default.
• W4306661090 cites W2222367475 @default.
• W4306661090 cites W2535591177 @default.
• W4306661090 cites W2559127842 @default.
• W4306661090 cites W2562156357 @default.
• W4306661090 cites W2744089945 @default.
• W4306661090 cites W2746164323 @default.
• W4306661090 cites W2790551104 @default.
• W4306661090 cites W2790796192 @default.
• W4306661090 cites W2922699454 @default.
• W4306661090 cites W2974328106 @default.
• W4306661090 cites W2998755980 @default.
• W4306661090 cites W3054436556 @default.
• W4306661090 cites W3134174432 @default.
• W4306661090 cites W3136567751 @default.
• W4306661090 cites W3137747360 @default.
• W4306661090 cites W3160088627 @default.
• W4306661090 cites W3200574709 @default.
• W4306661090 cites W4226000605 @default.
• W4306661090 doi "https://doi.org/10.21203/rs.3.rs-2045688/v1" @default.
• W4306661090 hasPublicationYear "2022" @default.
• W4306661090 type Work @default.
• W4306661090 citedByCount "0" @default.
• W4306661090 crossrefType "posted-content" @default.
• W4306661090 hasAuthorship W4306661090A5030291200 @default.
• W4306661090 hasAuthorship W4306661090A5056026487 @default.
• W4306661090 hasAuthorship W4306661090A5067372873 @default.
• W4306661090 hasBestOaLocation W43066610901 @default.
• W4306661090 hasConcept C121608353 @default.
• W4306661090 hasConcept C126322002 @default.
• W4306661090 hasConcept C141071460 @default.
• W4306661090 hasConcept C143998085 @default.
• W4306661090 hasConcept C168563851 @default.
• W4306661090 hasConcept C188261085 @default.
• W4306661090 hasConcept C197934379 @default.
• W4306661090 hasConcept C204243189 @default.
• W4306661090 hasConcept C2777658100 @default.
• W4306661090 hasConcept C2777863537 @default.
• W4306661090 hasConcept C2777982462 @default.
• W4306661090 hasConcept C2778182776 @default.
• W4306661090 hasConcept C502942594 @default.
• W4306661090 hasConcept C535046627 @default.
• W4306661090 hasConcept C71924100 @default.
• W4306661090 hasConceptScore W4306661090C121608353 @default.
• W4306661090 hasConceptScore W4306661090C126322002 @default.
• W4306661090 hasConceptScore W4306661090C141071460 @default.
• W4306661090 hasConceptScore W4306661090C143998085 @default.
• W4306661090 hasConceptScore W4306661090C168563851 @default.
• W4306661090 hasConceptScore W4306661090C188261085 @default.
• W4306661090 hasConceptScore W4306661090C197934379 @default.
• W4306661090 hasConceptScore W4306661090C204243189 @default.
• W4306661090 hasConceptScore W4306661090C2777658100 @default.
• W4306661090 hasConceptScore W4306661090C2777863537 @default.
• W4306661090 hasConceptScore W4306661090C2777982462 @default.
• W4306661090 hasConceptScore W4306661090C2778182776 @default.
• W4306661090 hasConceptScore W4306661090C502942594 @default.
• W4306661090 hasConceptScore W4306661090C535046627 @default.
• W4306661090 hasConceptScore W4306661090C71924100 @default.
• W4306661090 hasLocation W43066610901 @default.
• W4306661090 hasOpenAccess W4306661090 @default.
• W4306661090 hasPrimaryLocation W43066610901 @default.
• W4306661090 hasRelatedWork W2035624349 @default.

• next